Effects of Short-Term Methionine and Cysteine Restriction and Enrichment With Polyunsaturated Fatty Acids on Oral Glucose Tolerance, Plasma Amino Acids, Fatty Acids, Lactate and Pyruvate: Results From a Pilot Study

Thomas Olsen (✉ thomas.olsen@medisin.uio.no)
Universitetet i Oslo

Bente Øvrebø
University of Oslo: Universitetet i Oslo

Cheryl Turner
Oxford University: University of Oxford

Nasser Bastani
University of Oslo: Universitetet i Oslo

Helga Refsum
University of Oslo: Universitetet i Oslo

Kathrine Vinknes
University of Oslo: Universitetet i Oslo

Research note

Keywords: Methionine and Cysteine, Tolerance, Plasma Amino Acids, Fatty Acids

DOI: https://doi.org/10.21203/rs.3.rs-89344/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Objective

In this 7-day pilot study we randomized healthy, normal-weight men and women to either a dietary intervention with methionine and cysteine restriction enriched in PUFA (Met/Cys\textsubscript{low} + PUFA, n = 7) or with high contents of methionine, cysteine and SFA (Met/Cys\textsubscript{high} + SFA, n = 7). The objective was to describe the short-term responses in the oral glucose tolerance, amino acid profile, total fatty acid profile, pyruvate and lactate following a Met/Cys\textsubscript{low} + PUFA diet vs. Met/Cys\textsubscript{high} + SFA.

Results

The diet groups consisted of five women and two men, aged 20-38 years. After the 7-d intervention median pre- and post-oral glucose tolerance test (OGTT) glucose concentrations were 5 mmol/L and 4 mmol/L respectively, in the Met/Cys\textsubscript{low} + PUFA group. In the Met/Cys\textsubscript{high} + SFA group median pre- and post-OGTT glucose concentrations were 4.8 mmol/L and 4.65 mmol/L after the 7-d intervention. The response in the amino acid profile were similar in both groups during the intervention with the exception of serine. Fatty acids decreased from baseline to day 7 in both groups. Plasma lactate and pyruvate were similar for both groups with an increase to day 3 before approaching baseline values at day 7.

Trial registration

ClinicalTrials.gov: NCT02647970, registration date: 6 January 2016

Introduction

Methionine and cysteine are amino acids mainly found in foods of animal origin\textsuperscript{1}, and has roles in methylation reactions, protein synthesis and antioxidant production\textsuperscript{2}. Dietary restriction of the amino acid methionine and cysteine leads to many beneficial health effects in animals including increased lifespan, favorable changes in body composition and lipogenic gene expression, increased insulin sensitivity, and anti-inflammatory properties\textsuperscript{3}.

In animal studies, methionine and cysteine restriction can reduce activity of the lipogenic enzyme stearoyl CoA-desaturase (SCD1)\textsuperscript{4}. Circulating concentrations of cysteine are inversely associated with plasma SCD activity indices in large observational cohorts\textsuperscript{5}, further suggesting that amino acids may be involved in the regulation of the expression and/or activity of this enzyme in humans. SCD1 activity is also considered a target for supplementation with polyunsaturated fatty acids (PUFA) and intakes of PUFA-rich foods led to reduced plasma activity indices of SCD1 in a human intervention study\textsuperscript{6}. Experimental studies with either methionine and cysteine restriction, or PUFA supplementation, lead to many of same beneficial effects on metabolic outcomes\textsuperscript{3,7–9}. 
Over the recent years, we have performed and published results from one 7-d and one postprandial pilot study in which we observed effects of a diet restricted in methionine and cysteine and high in PUFAs on plasma sulfur amino acid profile and SCD1 activity indices\(^{10,11}\). Because the pilot studies were the first of its kind we also collected data on a wide range of potential outcomes including oral glucose tolerance, amino acid and total fatty acid profile as well as markers of glucose metabolism including pyruvate and lactate. The aim of the present paper was to systematically describe the response in oral glucose tolerance, amino acid profile, total fatty acid profile, pyruvate and lactate to a short-term dietary intervention with methionine and cysteine restriction plus enrichment of PUFA vs. a diet high in methionine, cysteine and saturated fatty acids (SFA).

**Materials And Methods**

Participants, inclusion and exclusion criteria, study design, collection of demographic variables, anthropometric measures, lifestyle and health-related data have been described in detail elsewhere\(^10\). In brief, 14 healthy, normal-weight men (n = 4) and women (n = 10) were recruited through the web and social media page of the University of Oslo. The study was a randomized controlled dietary intervention in which participants were randomized to either a dietary intervention with methionine and cysteine restriction enriched in PUFA (Met/Cys\(_{\text{low}}\)+PUFA, n = 7) or with high contents of methionine, cysteine and SFA (Met/Cys\(_{\text{high}}\)+SFA, n = 7). The energy content was on average 2000 kcal/d for women and 2500 kcal/d for men. Both diets were vegan-based without meat, fish, eggs, dairy products and certain plant-based foods. The Met/Cys\(_{\text{low}}\)+PUFA diet contained on average ~23.5 g total PUFA (10.9 % of total energy [E%]) and 0.93 g methionine and cysteine for women, and ~28 g total PUFA (10.6 E%) and 1.19 g methionine and cysteine for men. The Met/Cys\(_{\text{high}}\)+SFA contained 30.3 g SFA (13.5 E%) and 5.8 g methionine and cysteine for women, and 37.2 g SFA (13.3 E%) and 6.0 g methionine and cysteine for men. A full overview of the diet compositions and a typical daily menu can be found in the Additional file 1. The study protocol was approved by the Regional Committee for Medical Research Ethics South East and was registered with the United States National Library of Medicine Clinical Trials registry (ClinicalTrials.gov Identifier: NCT02647970, January 6\(^{\text{th}}\) 2016). The study was in accordance with the Declaration of Helsinki.

The oral glucose tolerance test (OGTT) procedure consisted of consumption of 75 g glucose in 4 dl of water g in the fasting state, and glucose measurements after 2 h.

Venous blood samples were collected at baseline, days 3 and 7 from each participant after an overnight fast for the amino acids, total fatty acids, lactate and pyruvate. The oral glucose tolerance test was performed at baseline and day 7. Samples were drawn in to EDTA-lined vacuum tubes and immediately centrifuged for five minutes at 4 °C. Plasma aliquots were stored at -80 °C until analysis. For lactate and pyruvate, due to the high instability of pyruvate in plasma, a plasma aliquot was immediately precipitated with 5-sulfosalicylic acid. The supernatant was stored at 80 °C until analysis.
Total plasma amino acids were measured by LC-MS/MS using a modified version of a previously described method. Briefly, isotopically labelled internal standards were added to plasma, followed by reduction of disulphides using dithioerythritol and then precipitation of the plasma proteins using 5-sulfosalicyclic acid. LC-MS/MS of the supernatant was carried out using a Shimadzu LC-20ADXR Prominence LC system (Kyoto, Japan) coupled to a Sciex QTRAP5500 mass spectrometer with a Turbo V ion source and Turbolonspray probe (Framingham, MA, USA). Chromatographic separation was achieved on a Phenomenex Kinetex Core Shell C18 (100 x 4.6 mm, 2.6 μm) column (Torrance, CA, USA). Plasma concentrations of lactate and pyruvate were determined by LC-MS/MS. Deuterium labelled lactate isotope was used as the internal standard. LC-MS/MS of the supernatant was performed using a Shimadzu LC-20ADXR LC system coupled to a Sciex QTRAP5500 mass spectrometer with Turbo V ion source and Turbolonspray probe (Framingham, MA, USA). Chromatographic separation of the analytes was achieved using a Restek Ultra AQ C18 (100 x 4.6 mm, 3 μm) column.

Plasma total fatty acid concentrations were determined by gas chromatography mass spectrometry (GC-MS) as described previously. Glucose concentrations were determined by colorimetric methods on a Cobas c702 analyzer (Roche Diagnostics International Ltd., Rotkreuz, Switzerland) at the Department of Medical Biochemistry (Oslo University Hospital Rikshospitalet, Oslo, Norway).

According to the CONSORT extension statement for pilot trials statistical hypothesis testing is actively discouraging because of the inherent uncertainty in data obtained from small samples, which are not powered to detect meaningful treatment effects. In line with this, we present findings in a descriptive manner with means and median as measures of central tendency and the standard deviation and range as measures of dispersion in tables presented in the additional files. In the plots we strive to present individual datapoints in addition to the mean and/or median as a measure of central tendency. Plots were made in R version 4.0.2 (R for statistical computing, Austria, Vienna) using packages “ggplot2” and “ggthemes”.

**Results**

In line with the CONSORT extension statement for pilot trials, we did not conduct formal hypothesis tests but report results in a descriptive manner. A flowchart of the participants can be found in Additional file 2. Characteristics of the study participants can be found in Additional file 3. In brief, each group consisted of 5 women and 2 men. Median (range) age was 31 (20, 37) and 24 (21, 38) years in the Met/Cys\textsubscript{low}+PUFA and Met/Cys\textsubscript{high}+SFA groups, respectively, whereas body mass index was 22.6 (21.0, 25) and 22.3 (20.7, 26.6) kg/m\textsuperscript{2} at baseline.

An overview of the metabolite response to the intervention is given in Additional file 4. The response in the OGTT is illustrated in Figure 1. At baseline, median (range) fasting glucose concentrations were 5.0 (4.5, 5.2) and 4.8 (4.3, 6.0) mmol/L, whereas two hours post-OGTT concentrations were 4.4 (2.9, 5.1) and 4.9 (3.8, 6.7) mmol/L in the Met/Cys\textsubscript{low}+PUFA and Met/Cys\textsubscript{high}+SFA groups, respectively. After the 7-d intervention, fasting glucose concentrations were 5.0 (4.7, 5.2) and 4.8 (4.2, 5.8) mmol/L, whereas two
hours post-OGTT concentrations were 4.0 (3.7, 4.9) and 4.65 (3.9, 6) mmol/L in the Met/Cys\textsubscript{low}+PUFA and Met/Cys\textsubscript{high}+SFA groups, respectively.

The response in plasma amino acid profile are illustrated in Figure 2. The sulfur amino acid response has been described in a previous publication \textsuperscript{10}. For the other amino acids, plasma concentrations responded similarly in both groups throughout the intervention with the exception of serine. Median (range) serine was 103 (76.4, 145) µmol/L in the Met/Cys\textsubscript{low}+PUFA group at baseline and 123 (74.4, 141) µmol/L at day 7. In the Met/Cys\textsubscript{high}+SFA group, plasma serine was 101 (59.8, 131) at baseline and 96.3 (65.5, 122) µmol/L at day 7.

The response in serum total fatty acid profile is illustrated in Figure 3. The fatty acid response was generally similar in both groups with decreases in most fatty acids from baseline to day 7.

The responses in plasma lactate and pyruvate are illustrated in Additional File 5 and were similar for both groups with an initial increase to day 3 before approaching baseline values at day 7.

**Discussion**

Despite the extensive research into sulfur amino acid restriction in animals \textsuperscript{3,9,15–19} and positive association with adverse health outcomes in human observational studies \textsuperscript{5,20,21}, this has surprisingly not been matched by human interventional studies with a few exceptions \textsuperscript{22,23}. In addition, the potential interaction of sulfur amino acid restriction and PUFA enrichment has not been addressed except for previously published pilot studies from our group \textsuperscript{10,11}. In this pilot study we describe the response in oral glucose tolerance, plasma amino acids and total fatty acid profile, lactate and pyruvate to a short-term diet restricted in the sulfur amino acids methionine and cysteine and enriched in PUFAs. Due to the descriptive nature of the study, we cannot draw firm conclusions but provide data that can aid the planning and design of future studies with respect to metabolic outcomes related to amino acid, fatty acids, insulin sensitivity and glucose metabolism.

Of particular interest is the short-term response in the OGTT where the median glucose concentrations after the dietary intervention were lower in the Met/Cys\textsubscript{low}+PUFA group (5 mmol/L pre-OGTT, 4 mmol/L post-OGTT) than in the Met/Cys\textsubscript{high}+SFA group (4.8 mmol/L pre-OGTT, 4.65 mmol/L post-OGTT). As this was a pilot study with no formal comparisons, this particular relationship may be worthy of further investigation. Although some work has been done in animals with respect to sulfur amino acids insulin sensitivity \textsuperscript{3,24,25}, data is currently lacking from human observational and experimental studies. One study showed that plasma concentrations of total cysteine were associated with insulin resistance in Hispanic adolescents \textsuperscript{26}, but more work is warranted and required preferably in long-term, adequately powered studies in individuals at risk of developing insulin resistance. Due to the combination of methionine and cysteine restriction and PUFA enrichment, we were not able to distinguish potential effects of amino acid
restriction from PUFA supplementation. However, effects of PUFA supplementation on glucose metabolism and insulin sensitivity is thought to be minimal as highlighted by a recent review and meta-analysis.\textsuperscript{27}

LIMITATIONS

The interpretation of these results is limited by the small sample size, and the short duration of the study and it is unlikely that meaningful effects could be detected during such a short period of time. In addition, there were considerable individual variation in both baseline concentrations and response in the markers, especially for the amino acids and fatty acids, further complicating the interpretation. Future studies can potentially overcome these limitations by enrolling more subjects to increase power. An additional limitation, especially with respect to the clinical relevance of the OGTT data, is that we included healthy normal-weight participants and future studies should address these issues in subjects with, or at risk of developing, metabolic complications. Because this was a descriptive study, we are not able to draw firm conclusions but these data may inform and be useful in the planning and design of future studies.

Abbreviations

\textit{Met/Cys}_{\text{low}}+\text{PUFA} : \text{Diet low in methionine and cysteine and high in polyunsaturated fatty acids}

\textit{Met/Cys}_{\text{high}}+\text{SFA} : \text{Diet high in methionine, cysteine and saturated fatty acids}

\textit{OGTT} : \text{Oral glucose tolerance test}

\textit{SCD} : \text{Stearoyl-CoA desaturase}

Declarations

\textit{Ethical approval and consent to participate}

This study was approved by the Regional Committee for Medical Research Ethics South East (Ref No. 2015/634). Written informed consent was obtained from all participants.

\textit{Consent for publication}

Not applicable.

\textit{Availability of data and material}

The data included in the current study are available from the corresponding author on reasonable request.

\textit{Competing interests}
None declared.

**Funding**

This work was funded by the Norwegian Research Council (Project number: 239948).

The Norwegian Research Council had no role in design or analysis of the project, or the writing of this manuscript.

**Authors’ contributions**

HR and KJV conceived the research questions, BØ, HR and KJV designed the study, CT and NEB were responsible for biochemical analyses, TO, CT, NEB and KJV collected the data, TO and KJV analyzed the data and drafted the manuscript, all authors read, revised and approved the final version of the manuscript.

**Acknowledgements**

The authors would like to thank Cynthia Prendergast and Anne-Randi Enget for technical assistance.

**References**

1. Nimni, M. E., Han, B. & Cordoba, F. Are we getting enough sulfur in our diet? *Nutr Metab* **4**, 24 (2007).
2. Brosnan, J. T. & Brosnan, M. E. The sulfur-containing amino acids: an overview. *J Nutr* **136**, 1636S-1640S (2006).
3. Dong, Z., Sinha, R. & Richie Jr., J. P. Disease prevention and delayed aging by dietary sulfur amino acid restriction: translational implications. *Ann N Y Acad Sci* **1418**, 44-55 (2018).
4. Perrone, C. E., Mattocks, D. A., Jarvis-Morar, M., Plummer, J. D. & Orentreich, N. Methionine restriction effects on mitochondrial biogenesis and aerobic capacity in white adipose tissue, liver, and skeletal muscle of F344 rats. *Metabolism* **59**, 1000-1011 (2010).
5. Vinknes, K. J. *et al.* Plasma sulfur amino acids and stearoyl-CoA desaturase activity in two caucasian populations. *Prostaglandins Leukot Essent Fat. Acids* **89**, 297-303 (2013).
6. Telle-Hansen, V. H. *et al.* Daily intake of cod or salmon for 2 weeks decreases the 18:1n-9/18:0 ratio and serum triacylglycerols in healthy subjects. *Lipids* **47**, 151-160 (2012).
7. Kim, H. J., Miyazaki, M. & Ntambi, J. M. Dietary cholesterol opposes PUFA-mediated repression of the stearoyl-CoA desaturase-1 gene by SREBP-1 independent mechanism. *J Lipid Res* **43**, 1750-1757 (2002).
8. Krishnan, S. & Cooper, J. A. Effect of dietary fatty acid composition on substrate utilization and body weight maintenance in humans. *Eur J Nutr* **53**, 691-710 (2014).
9. Ables, G. P., Perrone, C. E., Orentreich, D. & Orentreich, N. Methionine-restricted C57BL/6J mice are resistant to diet-induced obesity and insulin resistance but have low bone density. *PLoS One* **7**, e51357 (2012).

10. Olsen, T. *et al.* Combining dietary sulfur amino acid restriction with polyunsaturated fatty acid intake in humans: A randomized controlled pilot trial. *Nutrients* (2018) doi:10.3390/nu10121822.

11. Olsen, T. *et al.* Postprandial effects of a meal low in sulfur amino acids and high in polyunsaturated fatty acids compared to a meal high in sulfur amino acids and saturated fatty acids on stearoyl CoA-desaturase indices and plasma sulfur amino acids: a pilot study. *BMC Res. Notes* **13**, 379 (2020).

12. Antoniades, C. *et al.* MTHFR 677 C>T Polymorphism reveals functional importance for 5-methyltetrahydrofolate, not homocysteine, in regulation of vascular redox state and endothelial function in human atherosclerosis. *Circulation* **119**, 2507–2515 (2009).

13. Glaser, C., Demmelmaier, H. & Koletzko, B. High-throughput analysis of total plasma fatty acid composition with direct in situ transesterification. *PLoS One* **5**, e12045 (2010).

14. Eldridge, S. M. *et al.* CONSORT 2010 statement: extension to randomised pilot and feasibility trials. *Pilot Feasibility Stud* **2**, 64 (2016).

15. Ables, G. P. & Johnson, J. E. Pleiotropic responses to methionine restriction. *Exp Gerontol* (2017) doi:10.1016/j.exger.2017.01.012.

16. Elshorbagy, A. K. Body composition in gene knockouts of sulfur amino acid-metabolizing enzymes. *Mamm Genome* (2014) doi:10.1007/s00335-014-9527-x.

17. Elshorbagy, A. K., Smith, A. D., Kozich, V. & Refsum, H. Cysteine and obesity. *Obes. (Silver Spring)* **20**, 473–481 (2012).

18. Elshorbagy, A. K. *et al.* Cysteine supplementation reverses methionine restriction effects on rat adiposity: significance of stearoyl-coenzyme A desaturase. *J Lipid Res* **52**, 104–112 (2011).

19. Perrone, C. E. *et al.* Genomic and metabolic responses to methionine-restricted and methionine-restricted, cysteine-supplemented diets in Fischer 344 rat inguinal adipose tissue, liver and quadriceps muscle. *J Nutr. Nutr.* **5**, 132–157 (2012).

20. Elshorbagy, A. K. *et al.* S-adenosylmethionine is associated with fat mass and truncal adiposity in older adults. *J Nutr* **143**, 1982–1988 (2013).

21. Elshorbagy, A. K. *et al.* Homocysteine, cysteine, and body composition in the Hordaland Homocysteine Study: does cysteine link amino acid and lipid metabolism? *Am J Clin Nutr* **88**, 738–746 (2008).

22. Plaisance, E. P. *et al.* Dietary methionine restriction increases fat oxidation in obese adults with metabolic syndrome. *J Clin Endocrinol Metab* **96**, E836-40 (2011).

23. Olsen, T. *et al.* Effects of dietary methionine and cysteine restriction on plasma biomarkers, serum fibroblast growth factor 21, and adipose tissue gene expression in women with overweight or obesity: A double-blind randomized controlled pilot study. *J. Transl. Med.* (2020) doi:10.1186/s12967-020-02288-x.
24. Castano-Martinez, T. et al. Methionine restriction prevents onset of type 2 diabetes in NZO mice. *FASEB J* **33**, 7092–7102 (2019).

25. Elshorbagy, A. K. et al. Dietary cystine level affects metabolic rate and glycaemic control in adult mice. *J Nutr Biochem* **23**, 332–340 (2012).

26. Elshorbagy, A. K., Valdivia-Garcia, M., Refsum, H. & Butte, N. The association of cysteine with obesity, inflammatory cytokines and insulin resistance in Hispanic children and adolescents. *PLoS One* **7**, e44166 (2012).

27. Brown, T. J. et al. Omega-3, omega-6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: Systematic review and meta-analysis of randomised controlled trials. *BMJ* (2019) doi:10.1136/bmj.l4697.